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Objectives: To critically analyse radiotherapy cost studies published over the last 
35 years. MethOds: We conducted a comprehensive and systematic review of the 
literature searching for radiotherapy cost calculation studies on PubMed (Medline) 
and Embase databases and in the grey literature. The searches yielded 1327 unique 
entries that were evaluated against the following selection criteria: actual medical 
cost, external beam radiotherapy (EBRT), clear description of the cost calcula-
tion method. The review for compliance with the criteria was conducted in three 
phases: title; abstract and then full manuscript. Results: Since 1981, 50 studies 
satisfied our selection criteria. Any perspective, e.g. societal, institutional, was 
considered acceptable as long as the institutional resources ‘cost of radiotherapy 
was presented. Cost assessments of EBRT were conducted within a full economic 
evaluation framework (5 studies: 2 CEA, 2 CUA, and 1 CBA), cost analysis (24), cost 
description (18) and investment analysis (3). The scope of the selected studies 
ranged from comprehensive medical cost of radiotherapy including the depart-
ment’s overhead (20), to average cost specific to one pathology and/or treatment 
modality (25) to task-specific costs (7) e.g. shielding. Costs were computed per 
fraction and/or field (20), per treatment and/or patient (27) and specific to a treat-
ment’s process step (3). Costing methodologies ranged from detailed micro costing 
(13) to activity-based costing (5) to time-driven activity-based costing (2). Besides 
these established accounting methods, numerous “home-made” approaches were 
observed (23) and some studies didn’t state their method (7). cOnclusiOns: 
Due to heterogeneity both in methodology, input factors and paucity in costing 
method’s reporting, it was not possible to compare the cost estimates provided 
by these various studies. This comprehensive literature review of radiotherapy 
cost studies highlights the need for such studies to be conducted according to 
conventional accounting approaches and with rigor in the reporting of cost inputs 
and methodology.
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Objectives: The extended-release oxycodone hydrochloride is an opioid with 
similar action to morphine with proven efficacy in moderate to severe pain man-
agement. This study aims to develop a cost analysis of extended-release oxycodone 
versus morphine in an “if necessary” regime for cancer-related pain management, 
from the Brazilian public and private healthcare systems perspectives. MethOds: 
A decision model was developed to analyze the following strategies: group 1, 20 mg 
of extended-release oxycodone; group 2, 10 mg of extended-release oxycodone; 
and group 3, placebo. Efficacy data were obtained from Zhou e Wang, 2012. Direct 
costs were obtained from official price lists. Time horizon was determined through 
the hospital discharge period, and discount rates were not applied. Univariate sen-
sitivity analysis was performed to evaluate different hospital categories. Results: 
Total costs were 1,103 BRL, 1,071 BRL and 1,214 BRL per patient treated, from the 
public perspective, in groups 1, 2 and 3, respectively. The addition of oxycodone 
(10 and 20 mg) to the treatment reduced hospitalization stay, leading to savings 
of up to 143 BRL per patient, or a 12% reduction in total hospitalization cost. 
Total costs were 2,372 BRL, 2,367 BRL and 2,759 BRL per patient treated, from 
the private perspective, in groups 1, 2 and 3, respectively. The addition of oxyco-
done to treatment can lead to savings of up to 392.66 BRL per patient, a reduc-
tion about 14% of the total treatment cost during hospitalization. The univariate 
sensitivity analysis showed consistent results. cOnclusiOns: The inclusion of 
extended-release oxycodone can lead to a reduction in total costs related to pain 
treatment in patients with cancer, which would lead to resource savings for the 
payer.
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ToTaL aNNuaL CosT assoCiaTed WiTh BesT suPPoRTive CaRe of 
PaTieNTs WiTh uNReseCTaBLe advaNCed NoN-smaLL-CeLL LuNg 
CaNCeR uNdeR ReaL-WoRLd-CoNdiTioNs iN ReLaTioN To ResuLTs of 
iNTeRNaTioNaL sTudies
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Objectives: Only a few international studies give valid information about cost 
of Best Supportive Care (BSC) of patients with unresectable advanced or meta-
static non-small-cell lung cancer (NSCLC). The aim of this non interventional 
study was to compare the results of these studies with data collected under 
real-world-conditions in 26 oncological practices in Germany. MethOds: Data 
collected from oncological practices in Germany contain information about the 
entire course of treatment including the medication of primary disease, radio-
therapy, number of outpatient specialist visits, length of hospitalisation, type 
and number of diagnostic and laboratory procedures. In addition, four different 
studies from USA, Scotland, Great Britain and the Netherlands with information 
about cost of BSC were examined. To compare these studies with data from the 
oncological practices, the results were transferred into the german reimbursement 
systems for health care services. The calculation for annual cost of treatment is 
based on methods of the Institute for Quality and Efficiency in Healthcare (IQWiG) 
in Germany. Results: 509 patients with NSCLC from 26 oncological practices 
throughout Germany were included in the statistical and cost´s analysis. Patients 
cal trial population were included in the estimation of total cost. HCRU costs were 
estimated using the mean reimbursed amounts from a cohort of breast cancer 
patients from the Truven Health Marketscan database. Study drug costs were esti-
mated using the unit wholesale acquisition cost for T-DM1 and L+C. Monthly costs 
were calculated by dividing the total cost by the observed survival time (in months). 
Total costs were evaluated using the Kaplan Meier Sample Average (KMSA) estima-
tor to account for differences in the length of follow-up and censoring between 
trial arms. Results: In the EMILIA clinical trial, median overall survival was 30.9 
months with T-DM1 (n= 495) versus 25.1 months with L+C (n= 496) after a median of 
19 months follow-up. No differences were observed in the monthly cost per-patient 
between T-DM1 ($7,151, 95% confidence interval [CI]: $6,753 - $7,550) and L+C ($7,909, 
95% CI: $5,095 - $10,723). The KMSA mean total costs were $331,083 (95% CI: $152,238 
- $506,128) and $264,421 (95% CI: $133,143- $412,927) in the T-DM1 and L+C arms, 
respectively. Hospitalization costs were lower among the T-DM1 arm ($9,634, 95% CI: 
$6,394 - $12,873) than the L+C arm ($11,286, 95% CI: $6,216 - $16,357). cOnclusiOns: 
Although the mean total costs were higher for T-DMI because of longer survival rela-
tive to L+C, the average monthly costs of treating patients with T-DM1 were similar 
to L+C. This study, along with the 5.8-month survival benefit, supports the potential 
value of T-DM1 for the treatment of HER2+ metastatic or locally advanced breast 
cancer.
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Objectives: To evaluate and compare surgical parameters and costs associated 
with robotic and laparoscopic surgery for colorectal cancer over 5-years (2009-2014) 
in a single Italian centre. MethOds: From 2009 to 2014 data about laparoscopic 
(LAP) and robotic (ROB) assisted colorectal cancer procedures performed in General 
Surgery, University Hospital of Pisa were collected. Operating time and length of 
stay were evaluated as surgical parameters and costs included fixed and variable 
items. Amortised cost of the robot and laparoscopic instrument and amortised 
cost of robot maintenance per intervention were considered among fixed costs. 
Variable costs included costs of dispensable equipment, cost of operating room 
personnel per time and costs of length-of-stay. Over the 5-years period surgical 
parameters and costs associated with LAP and ROB were analysed using descriptive 
statistics and compared between groups by independent T-test and Mann-Whitney 
test. Generalized linear models were used to assess the independent effect of type 
of surgery and time. Results: A total of 25 laparoscopic (LAP) and 50 robotic (ROB) 
procedures were evaluated. Overall median operating time was significantly higher 
in LAP (270 min vs 312.5 min, P= 0.006) and regression analysis showed a borderline 
significant interaction effect between type of surgery and years (P= 0.058) suggesting 
a significant reduction of operating time in ROB but not in LAP. Hospital-stay did 
not differ between groups (P= 0.567). Overall mean costs associated to LAP varied 
between 8,612±2,733 Euros in 2009 to 10,827±5,038 Euros in 2013. For ROB mean costs 
were 12,966±1,115 Euros in 2010 to 11,933±1,753 Euros in 2014. Regression analysis 
outlined significant greater costs for ROB (P-value< 0.001) without differences over 
time. cOnclusiOns: Robotic surgery for colorectal cancer carries out significant 
greater costs and operating time compared to laparoscopic surgery. There is weak 
evidence of improvement in the exploitation of ROB procedures without significant 
consequences on costs at present.
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Objectives: Patients undergoing HCT are at risk for infections, especially dsDNA 
viral infections (cytomegalovirus, BK Virus, Epstein-Barr Virus, HHV-6, herpes sim-
plex, herpes zoster, and adenovirus), for which there are limited viable preventative 
pharmacotherapies. Our objective was to compare direct medical costs reimbursed 
by health insurers following HCT for patients with dsDNA viral infection versus 
those without infections. MethOds: MarketScan Research Databases were used to 
identify patients with a first (index) procedure code for HCT between 01-July-2009 
and 30-June-2014. Eligible patients were required to have 365 days of health plan 
enrollment prior to HCT to understand baseline factors. Reimbursements were 
tabulated for up to 365 days post-transplant; univariate Wilcoxon tests compared 
reimbursements for patients with at least one dsDNA infection versus patients 
with no dsDNA infection. Results: The cohort included 6,553 HCT patients with 
no dsDNA viral infection (2,111 [32%] allogeneic, 4,442 [68%] autologous) and 1,275 
patients with at least one dsDNA viral infection (924 [72%] allogeneic, 351 [28%] 
autologous). Mean (SD; IQR) reimbursements for the 365 days post-transplant were 
$218,151 (SD= $209,717; IQR= $94,873-$276,992) for HCT recipients without dsDNA 
infections versus $470,784 (SD= $467,557; IQR= $193,854-$588,019; p= 0.0001) for 
those with any dsDNA viral infection. Among allogeneic HCT recipients, reim-
bursements were higher. Mean (SD; IQR) costs post-transplant for allogeneic HCT 
recipients without infection were $320,320 (SD= $278,388; IQR= $ 53,191-$405,450) 
versus $551,664 (SD= $503,913; IQR= $261,318-$654,483; p< 0.0001) for patients with 
any dsDNA viral infection and $999,010 (SD= $822,223; IQR= $449,033-$1,410,000) 
for patients with adenovirus infection. Adenovirus infection represented 4.5% 
of all dsDNA viral infections. cOnclusiOns: Patients who experience dsDNA 
viral infection following HCT have a higher burden of reimbursement com-
pared to those without such infections. dsDNA virus infections are most com-
mon and more costly in allogeneic HCT recipients. Measures to prevent dsDNA 
viral infection following HCT could result in cost savings and improved patient 
outcomes.
